MDxHealth SA ADR - Asset Resilience Ratio
MDxHealth SA ADR (MDXH) has an Asset Resilience Ratio of 0.09% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MDXH strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how MDxHealth SA ADR's Asset Resilience Ratio has changed over time. See MDxHealth SA ADR (MDXH) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down MDxHealth SA ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MDxHealth SA ADR stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.00K | 0.09% |
| Total Liquid Assets | $110.00K | 0.09% |
Asset Resilience Insights
- Limited Liquidity: MDxHealth SA ADR maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MDxHealth SA ADR Industry Peers by Asset Resilience Ratio
Compare MDxHealth SA ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for MDxHealth SA ADR (2012–2023)
The table below shows the annual Asset Resilience Ratio data for MDxHealth SA ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.09% | $110.00K | $129.13 Million | +0.00pp |
| 2022-12-31 | 0.08% | $101.00K | $119.14 Million | -0.03pp |
| 2021-12-31 | 0.12% | $89.00K | $75.07 Million | -0.04pp |
| 2020-12-31 | 0.16% | $52.00K | $31.86 Million | +0.04pp |
| 2019-12-31 | 0.13% | $51.00K | $40.63 Million | +0.04pp |
| 2018-12-31 | 0.08% | $54.00K | $65.48 Million | +0.05pp |
| 2017-12-31 | 0.03% | $20.00K | $58.52 Million | -0.10pp |
| 2015-12-31 | 0.14% | $79.00K | $57.74 Million | 0.00pp |
| 2014-12-31 | 0.14% | $43.00K | $30.95 Million | -0.01pp |
| 2013-12-31 | 0.15% | $44.00K | $29.38 Million | +0.06pp |
| 2012-12-31 | 0.08% | $17.00K | $20.00 Million | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more